What LibiGel Is

VIDEO DESCRIPTION

Dr. Goldstein describes LibiGel and why women with menopause may be interested.

VIDEO TAGS

What LibiGel Is   doctor advice   dr irwin goldstein   empowher   HSDD in Women   libigel testosterone treatment   low libido in women   testosterone treatment for women   womens sexual healthWhat LibiGel Is   

VIDEO TRANSCRIPT

What LibiGel Is LibiGel is a topical form of testosterone that’s in a gel form that’s implied to the skin through a tube and would increase a woman’s testosterone. Nothing earth shattering about the concept. Prior to LibiGel there was an agent called Intrinsa, which was another topical form of testosterone delivered by a patch. Intrinsa, the sort of beginning of FDA studies for testosterone in women, went through again many thousands of women who were given either placebo or the active drug and the data on efficacy was accepted by the agency, but the data on safety were not accepted. There were several-year data and the agency wanted five or ten year data with hormones to see if there was a breast cancer or heart attack risk as was found in women who were in the Women’s Health Initiative who were taking this synthetic form of estrogen and synthetic form of progesterone. So, Intrinsa was timed oddly because it was introduced to the FDA around the same time of all of the emotional response to the estrogen and breast cancer care. So LibiGel took the FDA head on. The company is BioSante. The actual individual design of study is Michael Snabes and he is just a remarkable individual who said, “Okay, if the FDA wants ten-year data we are going to do ten-year data”. So actually here in San Diego we are part of a very large national clinical trial where we are taking women who have low interest and post-menopausal women and we are identifying if they get heart attacks and strokes while taking the medication. The cool part of the LibiGel series currently is they now have three year’s data. They have more than a thousand post-menopausal women in the trial. These data were presented to the Journal of Sexual Medicine and to meetings so I can share them with you, that in the three years they have a single breast cancer and they have a cardiovascular risk rate far less than the general population and the people that we need to study or that we are currently studying are women with diabetes and hypertension and smoking and older women where these events of heart attack and strokes and breast cancer would happen. So, while the data are not blinded, excuse me, while the data are still blinded, they are not unblinded so we don’t know which person got the breast cancer, was it the active drug or the placebo, the fact is, the risk is so low that it’s sort of a moot point who has that. So there is no signal of abnormal safety and this is a really cool concept so that one day we will now have flibanserin, a non-hormonal strategy to help women and theoretically, LibiGel, a hormonal strategy to help women and that would be major cool. We will be able to start to delve into the reasons for sexual problems in women with improved pharmacologic agents.

VIDEO SOURCE

http://www.contentdeity.com/video/451300256/What-LibiGel-Is.html

RELATED VIDEOS